In today’s Pharmaceutical Executive Daily, the White House withdraws its nomination of Dr. Heidi Overton for FDA commissioner just a day before her scheduled Senate committee vote amid abortion-related and MAHA-aligned concerns, a pharma licensing roundup covers Verismo Therapeutics’ deal with Stanford Medicine to advance in vivo CAR T-cell manufacturing and Pfizer’s agreement with Starna Therapeutics worth $330 million upfront and up to $2.3 billion in milestones for in vivo CAR-T programs in autoimmune disease, and Ankit Jain of Infinitus discusses how pharma should balance workloads between humans and agentic AI models.
The White House withdraws its nomination of Dr. Heidi Overton for FDA commissioner, pulling her name the night before a scheduled Senate committee vote amid skepticism from several Republican senators. Sen. Bill Cassidy says on X that the administration “abandoned a viable confirmation path for Dr. Overton,” whom he adds “would have had the votes to pass out of committee and pass the full Senate.” Pro-life senators reportedly want final assurances on mifepristone restrictions before confirming her, while some Make America Healthy Again-aligned officials distrust Overton as the main link between HHS Secretary Robert F. Kennedy Jr.’s policy priorities and White House aides who had stalled them.
Two in vivo CAR-T licensing deals advance efforts to engineer CAR T cells inside the body rather than manufacturing them outside it over several weeks. Verismo Therapeutics licenses Stanford Medicine’s Pack-IT technology, developed in Crystal Mackall’s lab, to extend its multi-chain KIR-CAR platform into in vivo engineering, building on early positive Phase I signals from Synkir-110 in solid tumors and Synkir-310 in B-cell malignancies. Separately, Pfizer signs an exclusive license with Starna Therapeutics worth $330 million upfront and up to $2.3 billion in milestones, gaining rights outside Greater China to three pre-IND in vivo CAR-T programs for autoimmune disease.
Finally, Pharmaceutical Executive speaks with Ankit Jain, chief executive officer and founder of Infinitus, on how pharma should balance workloads between humans and agentic AI. Jain argues the technology should be “agent-first, but human when it matters most,” with agents handling repetitive first-line contact and people stepping in for exceptions, complex analysis, and regulatory requirements. He contends that first line of contact has to be truly useful, contrasting it with the frustration patients felt toward older interactive voice response phone systems.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.